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 2 
Abstract 31 
The tumor microenvironment profoundly influences the behavior of recruited leukocytes and tissue resident 32 
immune cells.  These immune cells, which inherently have environmentally-driven plasticity necessary for 33 
their roles in tissue homeostasis, dynamically interact with tumor cells and the tumor stroma and play critical 34 
roles in determining the course of disease.  Among these immune cells, neutrophils were once considered 35 
much more static within the tumor microenvironment; however, some of these earlier assumptions were 36 
the product of the notorious difficulty in manipulating neutrophils in vitro. Technological advances that allow 37 
us to study neutrophils in context are now revealing the true roles of neutrophils in the tumor 38 
microenvironment. Here we discuss recent data generated by some of these tools and how it might be 39 
synthesized into more elegant ways of targeting these powerful and abundant effector immune cells in the 40 
clinic.  41 
 3 
Introduction 42 
Recent years have seen a resurgence in neutrophil biology in the context of cancer. Emerging data show that 43 
neutrophils are far from the simple homogeneous population they were once thought to be, and depending 44 
on context, neutrophil activity can differ in degrees towards pro- or even anti-tumor (1-3). Like other myeloid 45 
cells, neutrophils are highly influenced by their environment, therefore, fully understanding the interactions 46 
that occur between these cells and their surroundings will enable us to better target them during cancer 47 
progression and metastasis. Crucial to our anti-microbial response (4), neutrophils are produced in the tens 48 
of millions in the bone marrow and are the largest leukocyte population in the blood of humans.  As 49 
committed neutrophils are non-proliferative and equipped with an arsenal of proteolytic enzymes and self-50 
destructive effector strategies, they are notoriously hard to purify, manipulate, and study ex vivo.  This 51 
technical constraint, along with long held, but over-simplistic views of neutrophil biology (i.e. that they are 52 
homogenous and inflexible in their response) has meant that neutrophil cancer immunology has lagged 53 
behind that of lymphocytes or even the other myeloid cells. Fortunately, recent technological advances allow 54 
us to study better than ever how neutrophils contribute to and are influenced by the tumor 55 
microenvironment (TME) – both at the primary and secondary sites.  Here we review progress in this area 56 
and discuss the relative strengths and weaknesses of existing technology and tools to manipulate neutrophils 57 
along with examples of how they have benefited knowledge in the field, or in some cases argue why they 58 
should be applied to neutrophil biology next considering their contribution to other aspects of in situ cancer 59 
immunology.  60 
 61 
Neutrophil function at the primary tumor site 62 
The innate immune system co-evolved with infectious microorganisms and its actions are dominated by this 63 
primary function (5). Neutrophils contain potent anti-microbial molecules to counter microbial colonization 64 
and facilitate tissue repair. This deadly arsenal affords neutrophils the ability to counteract tumor formation 65 
and outgrowth (6-14). To recognize and phagocytize cancer cells, neutrophils can use Fc receptors and the 66 
immunoglobulins, IgG or IgA, through a process called antibody-dependent cellular toxicity (ADCC). Recent 67 
work has shown that blocking the interaction between CD47 – a ligand often expressed on cancer cells that 68 
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blocks phagocytosis – and its receptor, signal regulatory protein alpha (SIRPa), on neutrophils enhances 69 
ADCC (15). These observations have important implications for cancer immunotherapy, given that inhibitors 70 
to the CD47-SIRPa axis are currently being evaluated in cancer patients (16). Neutrophils can also delay 71 
tumorigenesis by presenting tumor antigens to killer CD8 T cells and secreting IL-12 to stimulate Type 1 72 
immunity and IFNg expression from CD4—CD8— unconventional ab T cells (11, 12, 17). However, many of the 73 
effector functions that are important in maintaining host tissue integrity also help tumors initiate and grow, 74 
via direct effects on cancer cells (18-21), remodeling the extracellular matrix (ECM) (22, 23), stimulation of 75 
angiogenesis (13, 24-35), activation of pro-tumorigenic macrophages (36), inhibition of anti-tumor immunity 76 
(35, 37-44), production of reactive oxygen species (ROS) (20, 24, 45, 46), or release of neutrophil extracellular 77 
traps (NETs) (42, 47-49) (Figure 1).  78 
Neutrophils arise from bone marrow progenitor cells, and tumors often secrete systemic factors, 79 
such as G-CSF, to stimulate granulopoiesis in the bone marrow (50-52). G-CSF is induced by IL-1b and IL-17A 80 
in autochthonous and transplantable mouse tumor models of breast and lung cancer (50, 53, 54), indicating 81 
that a number of tumor-initiated cell-cell communication events are often required to orchestrate 82 
granulopoiesis. In a Kras-driven, p53-deficient cancer model, tumors in the lung activate osteoblastic stromal 83 
cells in the bone marrow, which encourage the production of SiglecF-expressing neutrophils that promote 84 
cancer progression (55, 56). However, new research indicates that trained immunity (i.e. functional 85 
transcriptomic, epigenetic and metabolic reprogramming of innate immune cells evoked by foreign stimuli) 86 
can alter granulopoiesis and cancer progression. For example, the fungal-derivative b-glucan can rewire bone 87 
marrow progenitor cells through upregulation of Type I interferons to generate anti-tumor neutrophils that 88 
can slow the growth of B16 melanoma cells in mice (57). Once released from bone marrow, neutrophils are 89 
recruited to tumors by the CXCR2 ligands, CXCL1, CXCL2, CXCL5 and CXCL8 (in humans only) (22, 58-63), that 90 
are regulated by KRAS signaling (64), NOTCH signaling (65) and the transcription factor, SNAIL (35). Expression 91 
of the CXCL1 chemokine can also be enhanced by obesity in an IL-1b-driven mouse model of esophageal 92 
cancer (66), leading to increased neutrophil recruitment to tumors. Tumor growth is slowed in CXCR2-93 
deficient mice or CXCR2 inhibitor-treated mice in mouse models of lung, skin and intestinal cancer (22, 39, 94 
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58, 61-63, 67, 68), providing opportunities for therapeutic intervention. Indeed, CXCR2 inhibitors are being 95 
trialed in cancer patients (NCT04477343, NCT03161431, NCT03177187, PRIMUS003). 96 
Although the molecules regulating neutrophil expansion and recruitment to tumors are shared 97 
across the entire population, neutrophils can exhibit striking functional differences, and information on their 98 
diversity continues to emerge. The mechanisms by which neutrophils are polarized towards pro- or anti-99 
tumor states primarily occurs through cytokines, such as TGFb, IFNb, IFNg, G-CSF and GM-CSF (10-13, 26, 50, 100 
69). Tumor hypoxia is another important regulator of neutrophil phenotype and polarization, since 101 
counteracting hypoxia in an autochthonous mouse model of PTEN-driven uterine cancer decreases 102 
neutrophil-mediated cancer progression (70). The importance of neutrophil polarization and diversity in 103 
cancer has been recently reviewed elsewhere (1-3, 71, 72). However, it is important to mention that specific 104 
nomenclature describing neutrophil polarization states have led to confusion when comparing data in the 105 
field. These terms include N1/N2 neutrophils, which were coined to mirror T helper cell (Th)-1/2 immunity 106 
and M1/M2 macrophages; granulocytic or polymorphonuclear myeloid-derived suppressor cells (G/PMN-107 
MDSCs), which are T cell-inhibiting neutrophils; as well as low-density neutrophils (LDNs) and high-density 108 
neutrophils (HDNs), whose name stems from the location of neutrophils in density gradients. There are many 109 
biological arguments for and against the continued use of these terms (1, 2, 73, 74), but overall, we argue 110 
that to more accurately describe emerging data in the field they should be avoided. The terms above are 111 
either too narrow or too simplistic in their ability to capture the inherent plasticity of neutrophils, or they 112 
perpetuate the incorrect notion that N1, N2, MDSCs, LDNs, HDNs are cell populations distinct from 113 
neutrophils. These terms describe pathological activation or maturation states of neutrophils, rather than 114 
separate cell types (75). 115 
  116 
Neutrophil participation in metastasis 117 
The importance of neutrophils in cancer spread was established in the 1980s (76, 77), but not until recently 118 
have studies started to uncover the mechanisms of neutrophil function during the evolution of metastatic 119 
disease. Neutrophils can either help or hinder metastasis formation, independent of any action on primary 120 
tumor growth. To counteract metastasis, neutrophils can secrete H2O2 to kill cancer cells (7, 78) or 121 
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thrombospondin 1 (TSP1) to create an anti-metastatic environment in distant organs (79, 80). These cells can 122 
clear antibody-opsonized cancer cells in experimental liver metastasis models by ingesting plasma membrane 123 
fragments in a process called trogoptosis (81). However, most studies on this topic report on the ability of 124 
neutrophils to encourage metastasis.  125 
Neutrophils can promote metastasis from the vantage point of the primary tumor site by promoting 126 
escape of cancer cells into the vasculature (82), in the circulation where they provide mitogenic cues (83), or 127 
at the secondary site where these cells accumulate in a variety of models (50, 51, 65, 84-90). In visceral 128 
organs, neutrophils can direct disseminated cancer cells to specific locations (89, 91), promote vascular 129 
leakiness for easy extravasation (31, 32, 85) or suppress anti-tumor immunity by CD8 T cells and NK cells (50, 130 
51, 65, 69, 84, 86, 90-92). Recent data have provided new evidence of metabolic crosstalk between 131 
neutrophils and cancer cells, where neutrophils take up lipids from mesenchymal cells in the lung of 132 
mammary tumor-bearing mice and provide them to disseminated cancer cells as an additional energy source 133 
to fuel metastasis (93). Another pro-metastatic function of neutrophils is their ability to expel protein-134 
covered nucleic acids, known as neutrophil extracellular traps (NETs), that catch circulating cancer cells and 135 
stimulate their adhesion to endothelial cells, invasion and proliferation at secondary sites (23, 94-100). NETs 136 
are triggered from neutrophils by inflammatory agents such as lipopolysaccharide (LPS) or Cathepsin C, a 137 
cancer cell-secreted protease, in the lungs of mammary tumor-bearing mice to stimulate dormant, non-138 
cycling cancer cells into proliferating or to capture disseminated cancer cells from blood (100, 101). The 139 
complement molecule, C3a, also induces NETs and primary tumor progression in an Apc-mutated bowel 140 
cancer model (48). NETs activate a receptor on breast cancer cells, called coiled-coil domain containing 141 
protein 25 (CCDC25), that stimulates intracellular signaling via the ILK–b-parvin–RAC1–CDC42 pathway to 142 
promote metastasis formation (102). Whether CCDC25 is expressed by cancer cells across multiple tumor 143 
types or whether the interaction between NETs and cancer cells occurs through other receptors is unknown. 144 
Furthermore, neutrophil cooperation with platelets and platelet attachment to NETs can contribute to 145 
thrombosis. This poses a problem not only for the establishment of metastasis, but also for organ dysfunction 146 
at non-metastatic sites in cancer patients (103). 147 
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 The mechanisms by which tumors manipulate neutrophils provide opportunities for therapeutic 148 
intervention in cancer patients with metastatic disease. Crosstalk with other immune cells is critical in this 149 
process. For example, in autochthonous breast cancer mouse models, macrophages expressing IL-1b in 150 
primary tumors stimulate IL-17-producing gd T cells that control the expansion and phenotype of 151 
immunosuppressive neutrophils (50, 84). NK cells also regulate neutrophil behavior, as pro-metastatic 152 
neutrophils are converted to anti-metastatic neutrophils in NK cell-deficient mice (92); although, the 153 
mechanism by which this occurs is not clear. As mentioned above, TGFb is an important molecule for 154 
neutrophil polarization. Neutrophil-specific deletion of TGFb receptors decreases metastasis in breast and 155 
colorectal cancer models by reverting their suppression of anti-tumor immunity (65, 69). The atypical 156 
chemokine receptor, ACKR2, functions in a similar manner as TGFb in controlling the phenotype and activity 157 
of neutrophils. Whereas ACKR2-proficient neutrophils are pro-metastatic, ACKR2-deficient neutrophils are 158 
anti-metastatic (104).  159 
Another emerging indicator of neutrophil-driven metastasis is mutational status of tumors. An in-160 
depth comparison of 16 different autochthonous mouse models of breast cancer recently showed that 161 
neutrophil-mediated metastasis is dependent on p53 status in primary tumors. p53 null cancer cells increase 162 
expression of WNT ligands to activate IL-1b from tumor-associated macrophages, which in turn drive IL-17A 163 
production by gd T cells and neutrophil accumulation, while p53-proficient cancer cells do not (84). The 164 
upregulation of WNT ligands stemmed from the inability of p53 to suppress microRNA-34a expression, which 165 
subsequently suppresses WNT ligand expression. Using p53-deficient breast cancer models, inhibition of 166 
WNT ligands prevents both circulating and lung-infiltrating neutrophils and reduces pulmonary metastasis 167 
(84). Interestingly, loss of p53 in models of metastatic colorectal cancer fail to fit within this paradigm; 168 
instead, NOTCH1 signaling is the determining factor of neutrophil-mediated metastasis. Gut tumors driven 169 
by loss of p53 and KRAS hyperactivation do not metastasize to the liver, but when NOTCH1 signaling is added 170 
to this mutational combination, neutrophils are abundant and liver metastasis occurs (65). Moreover, 171 
epigenetic changes in renal cell carcinoma results in overexpression of CXCR2 ligands, neutrophilia and 172 
neutrophil-mediated lung metastasis that can be blocked with a bromodomain and extra-terminal motif 173 
inhibitor (BETi) (105). Breast cancer cells naturally producing Dickkopf-1 (DKK1), a regulator of the WNT 174 
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pathway that desensitizes cells to canonical WNT signaling, are inefficient at seeding the lung in part because 175 
DKK1 represses neutrophil recruitment to pulmonary tumors (106); although, it is unclear how the genetic 176 
makeup of these breast cancer cells results in overexpression of DKK1. These types of analyses should be 177 
extended to other tumor types to determine how tumor genotype dictates neutrophil responses. 178 
 179 
Implications for the clinic 180 
Because neutrophilia is a common feature in many cancer patients, blood neutrophil-to-lymphocyte ratio 181 
(NLR) is a useful and easily attainable biomarker to predict patient outcome, response to chemotherapy, and 182 
response to immunotherapy. A high NLR is generally associated with poor prognosis across multiple cancer 183 
types (107). NLR may be further refined by incorporating recent discoveries in neutrophil heterogeneity, 184 
using surface markers or nuclear morphology. Neutrophil subpopulations may be more pronounced at 185 
specific stages of cancer progression than others, so quantifying and using these subsets as biomarkers may 186 
be better prognostic indicators of disease severity. Indeed, the frequencies of neutrophil subsets as identified 187 
by mass cytometry (CyTOF) change as cancer progresses in melanoma patients (108). With this type of 188 
analysis, it will be important to determine optimal low, medium, and high thresholds of neutrophils subsets 189 
in order to parse confounding data from cancer patients with infections or other inflammatory diseases (a 190 
common side-effect of current immunotherapies), whose neutrophils will dynamically respond. 191 
In addition to circulating neutrophils, the density of neutrophils in primary tumors is often associated 192 
with poor outcome (2, 3) and frequently correlates inversely with T cell infiltration (109). CD66b and 193 
myeloperoxidase (MPO) are the most common markers used to identify neutrophils by 194 
immunohistochemistry; however, these markers are not exclusively specific to neutrophils and can be 195 
expressed by other myeloid cell populations. Using gene expression datasets, neutrophil-related gene 196 
signatures can also be used as prognostic indicators of outcome. In fact, using the computational method   197 
CIBERSORT to quantify cell populations from TCGA data, neutrophils are the greatest indicator of poor 198 
outcome among multiple immune cell populations across 39 different cancer types (110). 199 
Given their importance in primary tumor growth and metastasis, neutrophils represent a prime 200 
target for immunotherapy in patients with cancer. Three main strategies exist to modulate these cells via 201 
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interference with their recruitment, survival, or polarization. As discussed in more detail below, the most 202 
well studied method to block neutrophil recruitment is through CXCR2 inhibitors, which are currently being 203 
trialed in cancer patients. Neutrophils are very susceptible to various classes of chemotherapy due to their 204 
rapid turnover. However, chemotherapy-induced neutropenia may be advantageous in some cases, since 205 
this side-effect is associated with improved survival in patients with lung, breast, stomach, and colon cancer 206 
(111-114). Neutropenia comes with greater infection risk and must be carefully managed. Conversely, 207 
boosting neutrophils may be beneficial when these cells play an anti-tumor role. Increasing neutrophils can 208 
be accomplished through administration of G-CSF or GM-CSF. To alter neutrophil polarization and convert 209 
pro-tumor neutrophils into anti-tumor neutrophils, targeting cytokines, such as TGFb or IFNb, offers a viable 210 
approach. These strategies require further exploration with special consideration given to duration of 211 
treatment and toxicities. Furthermore, targeting neutrophil recruitment, survival, or polarization may 212 
synergize with other cancer immunotherapy modalities, such as checkpoint inhibitors, in patients resistant 213 
to these drugs. However, to fully implement neutrophil-related targets in the clinic, a greater understanding 214 
of neutrophil biology is required.  215 
 216 
Loss- and gain-of-function methods to study cancer-associated neutrophils 217 
Neutrophil depletion / Neutropenia 218 
Neutrophils are rapidly turned over, making depletion studies difficult, especially in long-term cancer models. 219 
The Gr1 antibody (RB6-8C5), which binds both Ly6C and Ly6G antigens, as well as the Ly6G antibody (1A8) 220 
are used in many studies to specifically target neutrophils (13, 50, 55, 115). However, other cell types can 221 
express Ly6C and G including monocytes and eosinophils, respectively, complicating interpretation. In 222 
addition, the low levels of Ly6G expressed on immature neutrophils means that these may be inefficiently 223 
depleted. Indeed, in a mouse model of head and neck cancer, depletion-resistant neutrophils were present 224 
in the tumor and spleen whilst being effectively depleted in the peripheral blood (116). During consistent 225 
depletion pressure, neutrophil numbers can rebound, and immature neutrophils can actually increase in 226 
tumor-bearing mice compared with controls.  227 
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Attempts at refining antibody-mediated depletion of neutrophils using anti-Ly6G together with 228 
secondary anti-rat antibody may afford more durable neutrophil depletion (117). Neutrophil trafficking is 229 
dependent on CXCR2 signaling; therefore, interference with CXCR2 via genetic deletion or pharmacological 230 
inhibitors are useful to block neutrophil ingress into tumors. As mentioned earlier, clinical trials are already 231 
underway of CXCR2 inhibitors in cancer patients. However, CXCR2 inhibitors can also affect CXCR2-expressing 232 
tumor cells and stromal cells (118, 119). The use of CXCR2 inhibitors may also induce compensatory 233 
mechanisms from other myeloid cells, as is observed in pancreatic cancer models (120). A preclinical model 234 
known as Genista mice lacks mature neutrophils due to a point mutation in Growth Factor Independence 1 235 
(Gfi1) (121) and has impaired NK cell responsiveness (122) but retains normal T and B cell differentiation. 236 
Transplantation of cancer cell lines into Genista mice suggests that neutrophils antagonize cancer 237 
progression by blocking the function of IL-17-producing gd T cells, which are well established promoters of 238 
tumor growth and metastasis (123). Neutrophils impede gd T cells through NOX-2-dependent production of 239 
ROS to inhibit their proliferation (124). Interestingly, these mice have a population of Ly6G intermediate cells, 240 
which potentially provides a model for studying immature neutrophils. To overcome these blunt approach 241 
models, conditional loss of function models have been developed. Mrp8-Cre mice crossed with diphtheria 242 
toxin receptor mice show 80-95% neutrophil depletion; although, there is minor leakage into the 243 
monocyte/macrophage compartment (125). 244 
 245 
Neutrophilia 246 
CXCR4 is important for retaining neutrophils in the bone marrow through interaction with its ligand CXCL12 247 
(126), and interference with this molecule can be used to promote neutrophilia. CXCR4-deficient mice die 248 
perinatally (127, 128). Therefore, CXCR4 manipulation has mainly relied on pharmacological antagonists, 249 
such as Plerixafor (AMD3100), which leads to a rapid release of neutrophils into the circulation. Mice with 250 
LysM-Cre-driven conditional deletion of Cxcr4, which specifically deletes CXCR4 in the entire myeloid 251 
compartment, exhibit neutrophilia. Melanoma cells transplanted into these mice have reduced growth and 252 
elicit increased NK cell cytotoxic response, indicative of anti-tumor polarized neutrophils (129). Clinical trials 253 
targeting CXCR4 to increase trafficking of anti-tumor immune cells in combination with T cell checkpoint 254 
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immunotherapy are underway in pancreatic cancer patients (NCT04177810). However, like CXCR2, CXCR4 is 255 
expressed by several cell types, suggesting caution is warranted in data interpretation. 256 
 257 
Neutrophil effector functions 258 
Collating the above-mentioned mouse models highlights the complexity and limitations of inducing 259 
neutropenia or neutrophilia to study the role of neutrophils in cancer. Knockout or conditional models are 260 
used to specifically target key neutrophil-derived molecules. The process of neutrophil extracellular trap 261 
production (NETosis) is dependent upon peptidylarginine deiminase 4 (PAD4), so PAD4-deficient mice are 262 
used to study NETs in cancer progression (23, 42, 49, 97, 130). Pancreatic tumor-bearing PAD4 knockout mice 263 
have even established the potential utility of combining NET inhibitors with T cell checkpoint inhibitors, such 264 
as anti-PD1 immunotherapy (42). Neutrophil myeloperoxidase (MPO), another enzyme highly abundant in 265 
neutrophils, leads to the generation of reactive oxygen (ROS) and nitrogen species (RNS). MPO knockout 266 
mice and inhibitors have been used in mouse models of lung cancer to delay tumor growth with some success 267 
(131). However, ROS production by neutrophils can also play a role in cancer cell killing (20, 24, 45, 46), but 268 
the context in which ROS is pro- or anti-tumor remains unresolved. Conditional models, such as Mrp8-Cre 269 
and LysM-Cre, are not entirely specific to neutrophils. The Ly6g-Cre (Catchup) mouse was generated to 270 
increase neutrophil specificity (132), and this mouse has been used to demonstrate the importance of TGFb-271 
mediated neutrophil polarization in liver metastasis (65) as TGFb is a major driver of pro-tumorigenic 272 
neutrophils in various models (13, 69). These data exemplify the utility of such mouse models. More 273 
sophisticated approaches aimed at targeting specific neutrophil effector molecules may shed some light on 274 
their role within cancer progression, but ultimately their combination with the more specialized techniques 275 
outlined below will likely improve our understanding.  276 
 277 
Spatially independent tools to study neutrophils  278 
Flow and Mass Cytometry 279 
As new insights into neutrophil diversity, maturity, and polarization are uncovered (1-3, 71, 72), methods to 280 
distinguish these different neutrophil populations become more important. Flow cytometry is an essential 281 
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tool in these efforts due to the ability to assess multiple molecules simultaneously. For example, in patients 282 
with non-small cell lung cancer (NSCLC), a 27-colour flow cytometry panel has been used to characterize the 283 
tumor immune landscape, which revealed neutrophils as the most abundant cell type in NSCLC tumors (109). 284 
New markers of neutrophil subsets, including CD10 (133), CD101 (65, 134), CD117/cKIT (50, 135-137), CD177 285 
(14) and SiglecF (55, 56), are easily interrogated by traditional flow cytometry methods. However, as the list 286 
of markers grows, data analysis becomes laborious. Automated gating algorithms, such as MegaClust, have 287 
aided comprehensive characterization of tumor-associated neutrophils within mouse models (35).  288 
Flow cytometry, though extremely valuable, still has limitations in the number of simultaneous 289 
markers possible. Mass cytometry combines flow cytometry and mass spectrometry, using stable isotope 290 
labelled antibodies analyzed by mass spectrometry to dramatically increase multiplexing (138).  This 291 
improvement is imperative for examining precious patient samples with limited total cell numbers. So far, in 292 
the context of cancer, neutrophils have mostly been investigated by mass cytometry in the circulation (108, 293 
139). Fluorescence-based cytometry has recently bridged the gap somewhat with mass cytometry, and 294 
better optical design and the use of spectrally resolved detectors now allow 30+ markers to be 295 
analyzed.  Fluorescence-based cytometry removes some of the constraints of mass cytometry, including the 296 
need for specialized kits and antibodies for stable isotope labeling and allows the possibility of sorting cells 297 
for downstream analysis (whereas mass cytometry destroys the sample).  Isolation of neutrophils can be 298 
difficult without altering their phenotype/activation status and therefore their functional response in ex vivo 299 
assays (140). However, fluorescence activated cell sorting (FACS) of neutrophils for transcriptomic profiling 300 
has been important in revealing their role in the TME (141).  301 
 302 
RNA sequencing 303 
Mostly due to accessibility, the first studies analyzing neutrophil transcripts in cancer have been performed 304 
on blood and bone marrow. RNAseq analysis of circulating neutrophils from K14-Cre;Cdh1F/F;Trp53F/F 305 
mammary tumor-bearing mice show an increase in expression of genes encoding the pro-metastatic proteins 306 
Prok2/Bv8, S100a8, S100a9 and Nos2 (which encodes inducible nitric oxide synthase (iNOS)) (50). 307 
Transcriptional analysis of sorted neutrophil populations from the blood of mice bearing liver metastases 308 
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from 4T1 mammary cancer cells has uncovered differences in expression of transcription factors, where 309 
neutrophils produce higher levels of C/EBPε (98). More recently the comparison of neutrophil transcripts 310 
from premetastatic lung and peripheral blood revealed the overexpression of lipid droplet-associated genes 311 
by pre-metastatic lung neutrophils, allowing the subsequent description of a neutrophil-fueled mechanism 312 
of breast cancer metastasis (93). 313 
Single cell (sc)RNAseq allows the detection of heterogeneity in maturation/activation markers in the 314 
wider population of neutrophils. Neutrophil heterogeneity in bone marrow, peripheral blood, and spleen has 315 
been recently assessed by scRNAseq in homeostasis and bacterial infection (142), but such a comprehensive 316 
study is still lacking in cancer. However, an analysis of human tumor biopsies and mouse models of lung 317 
cancer showed that neutrophils from humans and mice form a continuum of states with several shared 318 
populations amongst species (143). These populations consisted of canonical neutrophils expressing high 319 
levels of MMP8/9, S100A8/9 and ADAM8, and several tumor-specific neutrophils which were proposed to 320 
promote tumor growth in mice. In these studies, neutrophils exhibit very low transcript counts – a warning 321 
that neutrophils can inadvertently excluded using common data filters. Tumor-infiltrating neutrophils only 322 
partially overlap blood neutrophil populations, highlighting the influence of microenvironment on neutrophil 323 
phenotype (143). 324 
 325 
Spatially resolved tools to study neutrophils  326 
Visualizing neutrophils in their anatomical location can help understand how, where and when neutrophils 327 
influence tumor cells and other immune cells as well as their role in disease progression and therapy 328 
response. Using both routine and more advanced imaging techniques, the spatial context of tumor and 329 
stromal cells can be analyzed to investigate local clusters, cell dispersion and interactions in two to four 330 
dimensions (Figure 2). For example, immunohistochemistry (IHC) and immunofluorescence (IF) analyses of 331 
tumor and metastatic tissue are widely used to characterize neutrophils in tumors. Stratification of human 332 
tumors according to the presence of CD66b- or CD15-expressing neutrophils results in different prognostic 333 
significance depending on the tumor-type and cellular localization (144, 145). NETs have also been 334 
extensively analyzed in fixed tissues (49, 130, 146), usually quantified by co-localized immunofluorescence 335 
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staining of extracellular chromatin DNA with granule proteins (e.g. MPO; Neutrophil Elastase, NE; MMP9). 336 
NETosis implies chromatin decondensation which usually requires nuclear histone citrullination by PAD4. 337 
Therefore citrullinated histones are markers of NETosis but are dispensable in some conditions (147). Highly 338 
multiplexed imaging of tissue sections is achievable by multiplexed ion beam imaging (MIBI), which uses 339 
metal isotope-tagged antibodies in tissue sections in a similar way to mass cytometry. Using MIBI on triple 340 
negative breast cancer biopsies has revealed that neutrophils tend to cluster together and are enriched near 341 
the tumor border (148, 149). Furthermore, 3D imaging and tissue clearing techniques that reduce refractive 342 
indices and increase imaging depth are being employed to gain a deep understanding of neutrophil location 343 
and function throughout entire organs. Imaging neutrophil–T cell interactions in cleared human head and 344 
neck tumors has provided direct evidence that T cell activity is decreased when these cells are in close 345 
proximity to neutrophils (150). With multiple markers, these techniques could be used to better assess 346 
neutrophil heterogeneity (maturation, polarization, etc.) in the TME. 347 
 348 
In vivo Imaging  349 
The In Vivo Imaging System (IVIS) allows non-invasive, longitudinal fluorescence or bioluminescence imaging 350 
of living organisms albeit with limited resolution and sensitivity compared to microscopy. This method can 351 
be used to monitor neutrophils in vivo. Luminol, a compound that emits luminescence after oxidization, 352 
enables the imaging of MPO activity (151). In mice transplanted with 4T1 mammary cancer cells, MPO-353 
expressing neutrophils can be detected at the site of injection only two days after cancer cell transplantation, 354 
before tumors are palpable (152). Similarly, a probe to image Neutrophil Elastase Activity (Neutrophil 355 
Elastase 680 FAST imaging agent) has shown utility in cancer models (153, 154). 356 
 Intravital microscopy (IVM) is a high-resolution technique to gain valuable spatiotemporal 357 
information on cells of interest in mice (reviewed in (155-157)), including neutrophils. In transplantable 358 
mouse models of head and neck squamous cell carcinoma, IVM revealed that intratumoral neutrophils move 359 
slowly, compared with peritumoral neutrophils, which have a higher velocity that increases with cancer 360 
progression (158). NETs can also be imaged by IVM to visualize their effects on anti-tumor immune cells (47). 361 
Additionally, IVM has uncovered a role for neutrophils in transporting drug nanoparticles to tumors (159, 362 
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160). Neutrophil-dependent steps of the metastatic cascade, including neutrophil-mediated cancer cell 363 
adhesion to liver endothelium have been visualized by IVM (95, 161). However, some organs are easier to 364 
probe by IVM than others, such as the lung, which constantly moves. To overcome these mechanical issues, 365 
vacuum-stabilized imaging windows have been developed to visualize neutrophil behavior in the lung 366 
following tail vein injection of cancer cell lines (162). Neutrophil activation by cancer cells in situ can also be 367 
measured with imaging windows (47, 96, 163). Recent advances in permanent lung imaging windows for IVM 368 
(164) may allow monitoring of neutrophil behavior during the process of metastasis over time: from 369 
development of the pre-metastatic niche to cancer cell seeding to tumor outgrowth. 370 
Other animal models are extremely useful to study neutrophil dynamics in cancer. Zebrafish larvae 371 
are transparent and relatively small, so it is possible to track every neutrophil in the whole organism over 372 
extended periods of time (165). In zebrafish implanted with human estrogen receptor positive (ER+) breast 373 
cancer cells and neutrophils, neutrophils were observed to promote cancer cell invasion (166). 374 
 375 
Conclusion 376 
Recent mechanistic and technological advances have uncovered new aspects of neutrophil biology that offer 377 
potential avenues for therapeutic intervention. After years of lagging behind other immune cells, knowledge 378 
on neutrophil phenotype and function is finally growing. The community now has spatially independent and 379 
spatially resolved methodologies to address critical questions regarding neutrophil behavior. These 380 
methodologies should provide details on the context in which neutrophils help or hinder cancer progression. 381 
Given the new information on neutrophil diversity, lifespan, and physiological roles (167), these 382 
methodologies should be used (in combination) to interrogate neutrophil plasticity more 383 
comprehensively.  Like other myeloid cells, neutrophils exist in a wide spectrum of phenotypes driven by 384 
systemic, tumor-derived signals as well as local, tissue-specific microenvironments (167).  However, there is 385 
still a serious gap in our knowledge about how the TME and neutrophils influence each other both locally 386 
and systemically, and how these mechanisms differ between cancer types. With this information, we can 387 
understand the complex roles and responses of these cells during cancer progression and perhaps exploit 388 
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Figure Legends 868 
869 
Figure 1. Neutrophil functions during cancer progression. Neutrophils participate in tumor progression by 870 
acting both at primary tumors and the (pre-)metastatic niche. (A) In primary tumors, neutrophils can 871 
mediate angiogenesis through the release of MMP9, S100A8-A9 and BV8 to activate VEGF. The production 872 
of growth factors and laminin degradation by neutrophil-derived proteases NE and MMP9 can assist tumor 873 
cell proliferation. Alternatively, inflammatory stimuli (IL-1β and TNF-α) can induce neutrophil MET 874 
expression and binding of HGF, leading to NO production and tumor cell killing. Neutrophils also use 875 
antibody-dependent cellular cytotoxicity (ADCC) to kill cancer cells. (B) Neutrophils can support metastasis 876 
through a number of different factors individually or in combination. Inflammation induced by molecules 877 
such as S100A8 increases vascular permeability and therefore extravasation. Direct interactions between 878 
cancer cells and neutrophils or NETs can lead to their arrest in the vasculature. In addition, NETs have been 879 
suggested to wake dormant tumor cells and neutrophils can feed tumor cells with lipids to aid their 880 
survival. Together, these events favor tumor cell extravasation and metastasis. Neutrophils can also aid 881 
tumor cell killing. CCL2 produced by the primary tumor can activate neutrophils in the premetastatic niche 882 
to produce hydrogen peroxide providing an efficient tumor cell killing mechanism. IFN-β has also been 883 
shown to increase neutrophil anti-tumor potential by increasing NET capacity and cytotoxicity towards 884 
tumor cells (C) The release of reactive oxygen species (ROS) and nitric oxide (NO) can induce tumor cells 885 
 42 
death  but  conversely, through ROS, NO, ARG, PGE2, or a ‘shielding’ effect of NETs, neutrophils can 886 
suppress cytotoxic immune cell activity.  887 
 888 
 889 
Figure 2. Overlap in state-of-the-art of TME imaging approaches. Current state-of-the-art high-resolution 890 
imaging techniques allow highly multiplexed imaging in two dimensions with mass imaging or CODEX and to 891 
a lesser extent spectral imaging. It is possible to image large volumes of tissues and even whole organs in 892 
three dimensions using tissue clearing techniques in combination with light sheet, confocal or multiphoton 893 
microscopy but multiplexing options are currently sparse. To capture cell dynamics in vivo, imaging windows 894 
can be implanted in mice to image cells in situ in real time. However, tissue penetration and multiplexing 895 
options are again currently limited. The use of transparent organisms such as zebrafish embryos and the 896 
combination of volumetric imaging/intravital microscopy with spectral imaging could be a way to circumvent 897 
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